West Pharmaceutical Services, Inc. WST
370.44
(3.16)
(0.85%)
as of 25 Sep
- Market cap
- $26.3B
- P/E
- 47.1×
Follow WST
Indexes
indicate stock being part of an index,
Growth Flags
show if company had growth for consecutive years
| Jun '26 | Mar '26 | Dec '25 | Sep '25 | Older periods | |
|---|---|---|---|---|---|
P/E ratio |
45.62 | 33.33 | 40.28 | 38.63 |
+8 more quarters Free account |
P/S ratio |
7.64 | 5.60 | 6.47 | 6.28 | |
P/FCF ratio |
58.69 | 39.73 | 42.77 | 50.47 | |
P/Operating CF |
204.98 | 200.74 | 79.22 | 96.05 | |
P/B ratio |
8.50 | 6.03 | 6.26 | 6.21 | |
Price to Tangible BV |
8.84 | 6.28 | 6.50 | 6.46 | |
EV/Sales |
7.57 | 5.50 | 6.28 | 6.13 | |
EV/EBITDA |
29.22 | 21.32 | 25.52 | 24.59 | |
EV/Operating CF |
38.03 | 24.78 | 25.58 | 26.69 | |
EV/FCF |
58.15 | 39.03 | 41.51 | 49.33 | |
Quick Ratio |
1.79 | 1.79 | 2.09 | 1.97 | |
Current Ratio |
2.82 | 2.71 | 3.02 | 2.87 | |
Net Debt/EBITDA |
(1.03) | (1.43) | (2.89) | (2.02) | |
Debt/Assets |
4.98% | 4.93% | 4.75% | 4.94% | |
Debt/Equity |
0.07 | 0.07 | 0.06 | 0.07 | |
Asset Turnover |
0.83 | 0.83 | 0.78 | 0.78 | |
Operating CF/Net income |
0.81 | 0.65 | 1.90 | 1.41 | |
Capex/Depreciation |
(0.94) | (0.94) | (1.62) | (1.47) | |
Interest Coverage |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
2.26% | 1.87% | 2.71% | 2.13% | |
Selling, General and Administrative Expense of Revenue |
13.48% | 11.78% | 13.29% | 12.76% | |
Intangible Assets out of Total Assets |
0.03 | 0.03 | 0.03 | 0.03 | |
Share Based Compensation of Revenue |
1.25% | 0.78% | 0.83% | 1.04% | |
Graham Net Nets |
0.03 | 0.04 | 0.04 | 0.04 | |
Graham Number |
86.48 | 83.83 | 82.16 | 80.36 | |
Earnings Yield |
2.19% | 3.00% | 2.48% | 2.59% | |
Free Cash Flow Yield |
1.70% | 2.52% | 2.34% | 1.98% | |
Revenue per Share |
12.32 | 11.73 | 11.13 | 11.14 | |
Operating CF per Share |
1.75 | 1.25 | 3.47 | 2.73 | |
Capex per Share |
(0.61) | (0.59) | (1.05) | (0.88) | |
Free Cash Flow per Share |
1.14 | 0.66 | 2.42 | 1.85 | |
Cash per Share |
6.16 | 7.24 | 10.94 | 8.71 | |
Shareholders Equity per Share |
42.23 | 41.53 | 43.93 | 42.26 | |
Interest Debt per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Book value per Share |
42.23 | 41.53 | 43.93 | 42.26 | |
Free Cash Flow |
80.80 | 47.20 | 175.00 | 133.90 | |
Working Capital |
1,167.00 | 1,152.80 | 1,323.30 | 1,187.90 | |
Capital Expenditures |
(43.20) | (42.70) | (76.10) | (63.30) | |
Net Current Asset Value |
721.30 | 707.40 | 884.20 | 769.00 | |
EV/EBIT |
37.01 | 27.06 | 33.00 | 31.49 | |
Capex to Sales |
0.05 | 0.05 | 0.09 | 0.08 | |
Net Profit Margin |
17.65% | 16.43% | 16.41% | 17.40% | |
Price to Operating Income |
37.36 | 27.55 | 34.01 | 32.22 | |
| Other line items | |||||
Average Receivables |
647.20 | 614.60 | 563.45 | 574.65 | |
Average Payables |
245.85 | 240.35 | 246.50 | 240.05 | |
Average Inventory |
434.25 | 420.65 | 410.45 | 419.60 | |
Average Assets |
4,014.60 | 3,864.00 | 3,956.70 | 3,890.45 | |
Average Common Equity |
2,959.65 | 2,836.75 | 2,929.15 | 2,901.80 |
Columns are period end dates